DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF

1 - 90 . (canceled)

91 . A binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C—(X2)n, wherein

VD1 is a first variable domain;

VD2 is a second variable domain;

C is constant domain;

X1 is a linker;

X2 is an Fc region;

n is 0 or 1;

wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, wherein the binding protein is capable of binding IL-1β, and wherein the variable domains that form a functional target binding site for IL-1β comprise CDRs 1-3 from SEQ ID NO: 32 and CDRs 1-3 from SEQ ID NO: 33.

92 . The binding protein of claim 91 , wherein the variable domains that form functional binding sites for IL-1β comprise SEQ ID NO: 32 and SEQ ID NO: 33.

93 . A binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C—(X2)n, wherein

VD1 is a first variable domain;

VD2 is a second variable domain;

C is constant domain;

X1 is a linker;

X2 is an Fc region;

n is 0 or 1;

wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, and wherein the binding protein is capable of binding IL-1β and IL-17, wherein the variable domains in the functional binding site for IL-1β comprise CDRs 1-3 from SEQ ID NO: 32 and CDRs 1-3 from SEQ ID NO: 33.

94 . The binding protein of claim 93 , wherein the variable domains in the functional binding site for IL-1β comprise SEQ ID NO: 32 and SEQ ID NO: 33.

95 . The binding protein of claim 93 , wherein the variable domains in the functional binding site for IL-1β comprise CDRs 1-3 from SEQ ID NO: 32 and CDRs 1-3 from SEQ ID NO: 33, and a variable domain in the functional binding site for IL-17 comprises CDRs 1-3 from SEQ ID NO: 43.

96 . The binding protein of claim 93 , wherein the variable domains in the functional binding site for IL-1β comprise SEQ ID NO: 32 and SEQ ID NO: 33, and a variable domain in the functional binding site for IL-17 comprises CDRs 1-3 from SEQ ID NO: 43.

97 . The binding protein of claim 93 , wherein the variable domains in the functional binding site for IL-1β comprise CDRs 1-3 from SEQ ID NO: 32 and CDRs 1-3 from SEQ ID NO: 33, and a variable domain in the functional binding site for IL-17 comprises SEQ ID NO: 43.

98 . The binding protein of claim 91 , wherein the binding protein is also capable of binding IL-17, and wherein the variable domains that form a functional target binding site for IL-17 comprise

CDRs 1-3 from SEQ ID NO: 40 and CDRs 1-3 from SEQ ID NO: 41;

CDRs 1-3 from SEQ ID NO: 42 and CDRs 1-3 from SEQ ID NO: 43; or

CDRs 1-3 from SEQ ID NO: 44 and CDRs 1-3 from SEQ ID NO: 45.

99 . The binding protein of claim 92 , wherein the binding protein is also capable of binding IL-17, and wherein the variable domains that form a functional target binding site for IL-17 comprise

SEQ ID NO: 40 and SEQ ID NO: 41;

SEQ ID NO: 42 and SEQ ID NO: 43; or

SEQ ID NO: 44 and SEQ ID NO: 45.

100 . A binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C—(X2)n, wherein

VD1 is a first variable domain;

VD2 is a second variable domain;

C is constant domain;

X1 is a linker;

X2 is an Fc region;

n is 0 or 1;

wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, and wherein the binding protein is capable of binding IL-1β and IL-17, wherein:

(a) the variable domains that form a functional target binding site for IL-1β comprise SEQ ID NO: 32 and/or SEQ ID NO: 33, and

(b) the variable domains that form a functional target binding site for IL-17 comprise SEQ ID NO: 42 and/or SEQ ID NO: 43.

101 . The binding protein of claim 100 , wherein a variable domain in the functional binding site for IL-1β comprises SEQ ID NO: 33 and a variable domain in the functional binding site for IL-17 comprises SEQ ID NO: 43.

102 . The binding protein of claim 100 , wherein the variable domains in the functional binding site for IL-1β comprise SEQ ID NO: 32 and SEQ ID NO: 33, and a variable domain in the functional binding site for IL-17 comprises SEQ ID NO: 43.

103 . The binding protein of claim 91 , comprising first and second polypeptide chains, wherein

(a) the first polypeptide chain comprises a first VD1-(X1)n-VD2-C—(X2)n, wherein

VD1 is a first heavy chain variable domain;

VD2 is a second heavy chain variable domain;

C is a heavy chain constant domain;

X1 is a linker;

X2 is an Fc region;

n is 0 or 1; and

(b) the second polypeptide chain comprises a second VD1-(X1)n-VD2-C—(X2)n, wherein

VD1 is a first light chain variable domain;

VD2 is a second light chain variable domain;

C is a light chain constant domain;

X1 is a linker;

n is 0 or 1 for (X1)n; and

n is 0 for (X2)n.

104 . The binding protein of claim 91 , wherein the binding protein comprises:

SEQ ID NO: 54 and SEQ ID NO: 55;

SEQ ID NO: 56 and SEQ ID NO: 57;

SEQ ID NO: 74 and SEQ ID NO: 75;

SEQ ID NO: 76 and SEQ ID NO: 77;

SEQ ID NO: 94 and SEQ ID NO: 95;

SEQ ID NO: 96 and SEQ ID NO: 97;

SEQ ID NO: 114 and SEQ ID NO: 115;

SEQ ID NO: 116 and SEQ ID NO: 117;

SEQ ID NO: 134 and SEQ ID NO: 135;

SEQ ID NO: 136 and SEQ ID NO: 137;

SEQ ID NO: 154 and SEQ ID NO: 155;

SEQ ID NO: 156 and SEQ ID NO: 157;

SEQ ID NO: 174 and SEQ ID NO: 175;

SEQ ID NO: 176 and SEQ ID NO: 177;

SEQ ID NO: 194 and SEQ ID NO: 195;

SEQ ID NO: 196 and SEQ ID NO: 197;

SEQ ID NO: 214 and SEQ ID NO: 215;

SEQ ID NO: 216 and SEQ ID NO: 217;

SEQ ID NO: 234 and SEQ ID NO: 235;

SEQ ID NO: 236 and SEQ ID NO: 237;

SEQ ID NO: 254 and SEQ ID NO: 255;

SEQ ID NO: 256 and SEQ ID NO: 257;

SEQ ID NO: 274 and SEQ ID NO: 275; or

SEQ ID NO: 276 and SEQ ID NO: 277.

105 . The binding protein of claim 91 , comprising two first polypeptide chains and two second polypeptide chains and four functional target binding sites.

106 . The binding protein of claim 91 , wherein the binding protein

(a) binds IL-1β with a dissociation constant (K D ) of at most 4.2×10 −10 M, as measured by surface plasmon resonance,

(b) binds IL-17 with a dissociation constant (K D ) of at most 3.9×10 −10 M, as measured by surface plasmon resonance,

(c) neutralizes IL-1β with an EC 50 of at most 3.915 nM, as measured by a IL-1β neutralization assay, and/or

(d) neutralizes IL-17 with an EC 50 of at most 1.874 nM, as measured by a IL-17 neutralization assay.

107 . The binding protein of claim 91 , wherein X1 comprises at least one of SEQ ID NO: 1-29.

108 . The binding protein of claim 91 , wherein the Fc region is a variant sequence Fc region.

109 . The binding protein of claim 91 , wherein the Fc region is an IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD.

110 . A binding protein conjugate comprising the binding protein of claim 91 and an immunoadhesion molecule, an imaging agent, a therapeutic agent, or a cytotoxic agent.

111 . An isolated nucleic acid encoding the binding protein amino acid sequence of claim 91 .

112 . A vector comprising the isolated nucleic acid of claim 111 .

113 . A host cell comprising the vector of claim 112 , wherein the host cell is selected from a group consisting of a prokaryotic cell, Escherichia coli , a eukaryotic cell, an animal cell, a plant cell, a fungal cell, a yeast cell, an Sf9 cell, a mammalian cell, an avian cell, an insect cell, a CHO cell, and a COS cell.

114 . A method of producing a binding protein, comprising culturing the host cell of claim 113 in culture medium under conditions sufficient to produce the binding protein.

115 . A pharmaceutical composition comprising the binding protein of claim 91 and a pharmaceutically acceptable carrier.

116 . The pharmaceutical composition of claim 115 , further comprising at least one additional therapeutic agent.

117 . The pharmaceutical composition of claim 116 , wherein the therapeutic agent is selected from a group consisting of an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional fragment thereof, methotrexate, cyclosporine, rapamycin, FK506, a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

118 . A method of treating a subject for a disease or a disorder, comprising administering the binding protein of claim 91 to the subject.

119 . The method of claim 118 , wherein the disease or the disorder is selected from a group consisting of rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, septic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel disease, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis scleroderma, graft versus host disease, organ transplant rejection, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpurea, microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, infectious diseases, parasitic diseases, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, malignancies, heart failure, myocardial infarction, Addison's disease, sporadic, polyglandular deficiency type I and polyglandular deficiency type II, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia greata, seronegative arthropathy, arthropathy, Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic synovitis, chlamydia, yersinia and salmonella associated arthropathy, spondyloarthropathy, atheromatous disease/arteriosclerosis, atopic allergy, autoimmune bullous disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune haemolytic anaemia, Coombs positive haemolytic anaemia, acquired pernicious anaemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cryptogenic autoimmune hepatitis, acquired immunodeficiency disease syndrome, acquired immunodeficiency related diseases, hepatitis B, hepatitis C, common varied immunodeficiency (common variable hypogammaglobulinaemia), dilated cardiomyopathy, female infertility, ovarian failure, premature ovarian failure, fibrotic lung disease, cryptogenic fibrosing alveolitis, post-inflammatory interstitial lung disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus associated lung disease, dermatomyositis/polymyositis associated lung disease, Sjögren's disease associated lung disease, ankylosing spondylitis associated lung disease, vasculitic diffuse lung disease, haemosiderosis associated lung disease, drug-induced interstitial lung disease, fibrosis, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycaemia, type B insulin resistance with acanthosis nigricans, hypoparathyroidism, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, osteoarthrosis, primary sclerosing cholangitis, psoriasis type 1, psoriasis type 2, idiopathic leucopaenia, autoimmune neutropaenia, renal disease NOS, glomerulonephritides, microscopic vasulitis of the kidneys, lyme disease, discoid lupus erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Sjörgren's syndrome, Takayasu's disease/arteritis, autoimmune thrombocytopaenia, idiopathic thrombocytopaenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis, vitiligo acute liver disease, chronic liver diseases, alcoholic cirrhosis, alcohol-induced liver injury, cholestasis, idiosyncratic liver disease, Drug-Induced hepatitis, Non-alcoholic Steatohepatitis, allergy and asthma, group B streptococci (GBS) infection, mental disorders, depression, schizophrenia, Th2 Type and Th1 Type mediated diseases, acute pain, chronic pain, cancer, lung cancer, breast cancer, stomach cancer, bladder cancer, colon cancer, pancreatic cancer, ovarian cancer, prostate cancer, rectal cancer, hematopoietic malignancies, leukemia, lymphoma, abetalipoprotemia, acrocyanosis, acute and chronic parasitic or infectious processes, acute leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute or chronic bacterial infection, acute pancreatitis, acute renal failure, adenocarcinomas, aerial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis, allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allograft rejection, alpha-1-antitrypsin deficiency, amyotrophic lateral sclerosis, anemia, angina pectoris, anterior horn cell degeneration, anti cd3 therapy, antiphospholipid syndrome, anti-receptor hypersensitivity reactions, aortic and peripheral aneuryisms, aortic dissection, arterial hypertension, arteriosclerosis, arteriovenous fistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrial flutter, atrioventricular block, B cell lymphoma, bone graft rejection, bone marrow transplant (BMT) rejection, bundle branch block, Burkitt's lymphoma, burns, cardiac arrhythmias, cardiac stun syndrome, cardiac tumors, cardiomyopathy, cardiopulmonary bypass inflammation response, cartilage transplant rejection, cerebellar cortical degenerations, cerebellar disorders, chaotic or multifocal atrial tachycardia, chemotherapy associated disorders, chronic myelocytic leukemia (CML), chronic alcoholism, chronic inflammatory pathologies, chronic lymphocytic leukemia (CLL), chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, colorectal carcinoma, congestive heart failure, conjunctivitis, contact dermatitis, cor pulmonale, coronary artery disease, Creutzfeldt-Jakob disease, culture negative sepsis, cystic fibrosis, cytokine therapy associated disorders, Dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever, dermatitis, dermatologic conditions, diabetes, diabetes mellitus, diabetic ateriosclerotic disease, diffuse Lewy body disease, dilated congestive cardiomyopathy, disorders of the basal ganglia, Down's syndrome in middle age, drug-induced movement disorders induced by drugs which block CNS dopamine receptors, drug sensitivity, eczema, encephalomyelitis, endocarditis, endocrinopathy, epiglottitis, epstein-barr virus infection, erythromelalgia, extrapyramidal and cerebellar disorders, familial hematophagocytic lymphohistiocytosis, fetal thymus implant rejection, Friedreich's ataxia, functional peripheral arterial disorders, fungal sepsis, gas gangrene, gastric ulcer, glomerular nephritis, graft rejection of any organ or tissue, gram negative sepsis, gram positive sepsis, granulomas due to intracellular organisms, hairy cell leukemia, Hallervorden-Spatz disease, Hashimoto's thyroiditis, hay fever, heart transplant rejection, hemachromatosis, hemodialysis, hemolytic uremic syndrome/thrombolytic thrombocytopenic purpura, hemorrhage, hepatitis A, His bundle arrythmias, HIV infection/HIV neuropathy, Hodgkin's disease, hyperkinetic movement disorders, hypersensitivity reactions, hypersensitivity pneumonitis, hypertension, hypokinetic movement disorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathic Addison's disease, idiopathic pulmonary fibrosis, antibody mediated cytotoxicity, asthenia, infantile spinal muscular atrophy, inflammation of the aorta, influenza A, ionizing radiation exposure, iridocyclitis/uveitis/optic neuritis, ischemia-reperfusion injury, ischemic stroke, juvenile rheumatoid arthritis, juvenile spinal muscular atrophy, Kaposi's sarcoma, kidney transplant rejection, legionella , leishmaniasis, leprosy, lesions of the corticospinal system, lipedema, liver transplant rejection, lymphedema, malaria, malignant lymphoma, malignant histiocytosis, malignant melanoma, meningitis, meningococcemia, metabolic/idiopathic, migraine headache, mitochondrial multi.system disorder, mixed connective tissue disease, monoclonal gammopathy, multiple myeloma, multiple systems degenerations, Mencel Dejerine-Thomas Shi-Drager degeneration, Machado-Joseph degeneration, myasthenia gravis, mycobacterium avium intracellulare, mycobacterium tuberculosis , myelodyplastic syndrome, myocardial infarction, myocardial ischemic disorders, nasopharyngeal carcinoma, neonatal chronic lung disease, nephritis, nephrosis, neurodegenerative diseases, neurogenic muscular atrophies, neutropenic fever, non-hodgkins lymphoma, occlusion of the abdominal aorta and its branches, occulsive arterial disorders, okt3 therapy, orchitis/epidydimitis, orchitis/vasectomy reversal procedures, organomegaly, osteoporosis, pancreas transplant rejection, pancreatic carcinoma, paraneoplastic syndrome/hypercalcemia of malignancy, parathyroid transplant rejection, pelvic inflammatory disease, perennial rhinitis, pericardial disease, peripheral arteriosclerotic disease, peripheral vascular disorders, peritonitis, pernicious anemia, pneumocystis carinii pneumonia, pneumonia, POEMS syndrome, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes syndrome, post perfusion syndrome, post pump syndrome, post-MI cardiotomy syndrome, preeclampsia, progressive supranuclear palsy, primary pulmonary hypertension, radiation therapy, Raynaud's phenomenon and disease, Raynoud's disease, Refsum's disease, regular narrow QRS tachycardia, renovascular hypertension, reperfusion injury, restrictive cardiomyopathy, sarcomas, scleroderma, senile chorea, senile dementia of Lewy body type, seronegative arthropathies, shock, sickle cell anemia, skin allograft rejection, skin changes syndrome, small bowel transplant rejection, solid tumors, specific arrythmias, spinal ataxia, spinocerebellar degenerations, streptococcal myositis, structural lesions of the cerebellum, subacute sclerosing panencephalitis, Syncope, syphilis of the cardiovascular system, systemic anaphalaxis, systemic inflammatory response syndrome, systemic onset juvenile rheumatoid arthritis, T-cell or FAB ALL, telangiectasia, thromboangitis obliterans, thrombocytopenia, toxicity, transplants, trauma/hemorrhage, type III hypersensitivity reactions, type IV hypersensitivity, unstable angina, uremia, urosepsis, urticaria, valvular heart diseases, varicose veins, vasculitis, venous diseases, venous thrombosis, ventricular fibrillation, viral and fungal infections, viral encephalitis/aseptic meningitis, viral-associated hemaphagocytic syndrome, Wernicke-Korsakoff syndrome, Wilson's disease, xenograft rejection of any organ or tissue, acute coronary syndromes, acute idiopathic polyneuritis, acute inflammatory demyelinating polyradiculoneuropathy, acute ischemia, adult Still's disease, alopecia greata, anaphylaxis, anti-phospholipid antibody syndrome, aplastic anemia, arteriosclerosis, atopic eczema, atopic dermatitis, autoimmune dermatitis, autoimmune disorder associated with streptococcus infection, autoimmune enteropathy, autoimmune hearing loss, autoimmune lymphoproliferative syndrome (ALPS), autoimmune myocarditis, autoimmune premature ovarian failure, blepharitis, bronchiectasis, bullous pemphigoid, cardiovascular disease, catastrophic antiphospholipid syndrome, celiac disease, cervical spondylosis, chronic ischemia, cicatricial pemphigoid, clinically isolated syndrome (cis) with risk for multiple sclerosis, conjunctivitis, childhood onset psychiatric disorder, chronic obstructive pulmonary disease (COPD), dacryocystitis, dermatomyositis, diabetic retinopathy, diabetes mellitus, disk herniation, disk prolapse, drug induced immune hemolytic anemia, endocarditis, endometriosis, endophthalmitis, episcleritis, erythema multiforme, erythema multiforme major, gestational pemphigoid, Guillain-Barré syndrome (GBS), hay fever, Hughes syndrome, idiopathic Parkinson's disease, idiopathic interstitial pneumonia, IgE-mediated allergy, immune hemolytic anemia, inclusion body myositis, infectious ocular inflammatory disease, inflammatory demyelinating disease, inflammatory heart disease, inflammatory kidney disease, IPF/UIP, iritis, keratitis, keratoconjunctivitis sicca, Kussmaul disease or Kussmaul-Meier disease, Landry's paralysis, Langerhan's cell histiocytosis, livedo reticularis, macular degeneration, microscopic polyangiitis, morbus bechterev, motor neuron disorders, mucous membrane pemphigoid, multiple organ failure, myasthenia gravis, myelodysplastic syndrome, myocarditis, nerve root disorders, neuropathy, non-A non-B hepatitis, optic neuritis, osteolysis, pauciarticular JRA, peripheral artery occlusive disease (PAOD), peripheral vascular disease (PVD), peripheral artery, disease (PAD), phlebitis, polyarteritis nodosa, periarteritis nodosa, polychondritis, polymyalgia rheumatica, poliosis, polyarticular JRA, polyendocrine deficiency syndrome, polymyositis, polymyalgia rheumatica (PMR), post-pump syndrome, primary Parkinsonism, prostatitis, pure red cell aplasia, primary adrenal insufficiency, recurrent neuromyelitis optica, restenosis, rheumatic heart disease, sapho (synovitis, acne, pustulosis, hyperostosis, and osteitis), scleroderma, secondary amyloidosis, shock lung, scleritis, sciatica, secondary adrenal insufficiency, silicone associated connective tissue disease, sneddon-wilkinson dermatosis, spondilitis ankylosans, Stevens-Johnson syndrome (SJS), systemic inflammatory response syndrome, temporal arteritis, toxoplasmic retinitis, toxic epidermal necrolysis, transverse myelitis, TRAPS (tumor necrosis factor receptor, type 1 allergic reaction, type II diabetes, urticaria, usual interstitial pneumonia (UIP), vasculitis, vernal conjunctivitis, viral retinitis, Vogt-Koyanagi-Harada syndrome (VKH syndrome), wet macular degeneration, wound healing, Yersinia , and salmonella associated arthropathy.

120 . The method of claim 118 or 119 , wherein the disease or the disorder is selected from a group consisting of systemic lupus erythematosus, asthma, multiple sclerosis, rheumatoid arthritis, osteoarthritis, psoriasis, psoriatic arthritis, inflammatory disorders, autoimmune disorders, sepsis, Alzheimer's disease, Parkinson's disease, neurological disorders, neurodegenerative disorders, neuronal regeneration, spinal cord injury, and oncological disorders.

121 . A method of determining the presence, amount, or concentration of IL-1β and/or IL-17 in a test sample by an immunoassay,

wherein the immunoassay comprises contacting the test sample with at least one binding protein and at least one detectable label, and

wherein the at least one binding protein comprises the binding protein of claim 91 .

122 . A kit for assaying a test sample for the presence, amount, or concentration of IL-1β and/or IL-17, the kit comprising

(a) instructions for assaying the test sample for IL-1β and/or IL-17 and

(b) at least one binding protein comprising the binding protein of claim 91 .